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Abstract
Background: Russia is one of the very few industrialised countries in the world where life
expectancy has been declining. Alcohol has been implicated as a major contributor to the rapid
fluctuations observed in male life expectancy since 1985 that have been particularly marked among
working-age men.
One approach to reducing the alcohol problem in Russia is 'brief interventions' which seek to
change views of the personal acceptability of excessive drinking and to encourage self-directed
behaviour change. There is limited understanding in Russia of the salience and applicability of
Motivational Interviewing (MI), a well-defined brief intervention commonly used to target alcohol-
related behaviour, but MI may have important potential for success within the Russian context.
Methods/Design:  The study will be an individually randomised two-armed parallel group
exploratory trial. The primary hypothesis is that a brief adaptation of MI will be effective in reducing
self-reported hazardous drinking at 3 months. The secondary hypothesis is that it will be effective
in reducing self-reported past week beverage alcohol consumption, alcohol dependence and
related problems at 3 months and at 12 months. MI will also be effective at 12 months in reducing
self-reported hazardous drinking, alcohol dependence and related problems, proxy reported
hazardous drinking, and recent alcohol use as indicated by bio-markers.
Participants are drawn from the Izhevsk Family Study II, with eligibility determined based on proxy
reports of hazardous drinking in the past year. All participants undergo a health check, with MI
subsequently delivered to those in the intervention arm. Signed consent is obtained from those in
the intervention arm at this point. Both groups are then invited for 3 and 12 month follow ups. The
control group will not receive any additional intervention.
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Background
What is the problem?
Russia is one of the very few industrialised countries in the
world where life expectancy has been declining [1]. Anal-
ysis of routinely collected data over the past few decades
has implicated alcohol as a major contributor to the rapid
fluctuations observed in male life expectancy since 1985,
that have been particularly marked among working-age
men. For example, there was an increase in life expectancy
following the start of the anti-alcohol campaign in 1985
[2] that led to falls in levels of per capita alcohol con-
sumption in Russia [3-5] Rates of mortality from alcohol-
related deaths among working age men decreased particu-
larly sharply [5]. However, with the collapse of the Soviet
Union this progress was reversed with a 6-year decline in
male life expectancy between 1990 and 1994 that coin-
cided with increases in per capita alcohol consumption.
There is growing evidence linking excessive alcohol con-
sumption to the high mortality among working age men
in Russia [6,7]. A recent study demonstrated the large role
played by alcohol, and in particular, of hazardous drink-
ing patterns including a phenomenon termed "zapoi"
(episodes of extended periods of drunkenness during
which the participant withdraws from normal life), and
consumption of surrogate alcohols (alcoholic substances
not intended to be drunk, also known as non-beverage
alcohols) in deaths from all causes and alcohol-related
causes among men of working age in Russia [7].
What is the evidence so far about what works to reduce 
alcohol problems?
One important approach to reducing the alcohol problem
in Russia would be through government action to control
manufacture and sale of drinkable surrogates and limit
the availability and increase in price of legitimate alco-
holic beverages. However there is also an urgent need to
develop individual-level treatment services that are effec-
tive in the Russian context, where there has been little or
no employment of individual counselling. There is an
additional need to reach beyond specialist treatment serv-
ices, as the majority of hazardous and harmful drinkers
elsewhere do not access such provisions.
Another approach that may be appropriate is that of 'brief'
interventions. These seek to change views of the personal
acceptability of excessive drinking and to encourage self-
directed behaviour change. They include both simple
forms of advice and brief counselling techniques. Wide-
spread dissemination of these interventions is possible as
they can be delivered by a wide range of generic rather
than specialist practitioners. These techniques have been
shown to be effective in many other contexts. An interna-
tional evidence-base has accumulated over more than 20
years, with efficacy data originating mainly, but not exclu-
sively, from English language speaking countries. Reduc-
tions in volume of alcohol consumed are typically about
20–25% [8] and reductions in the proportions of hazard-
ous drinkers are between 10–19% [9] The number needed
to treat is about 8 for both hazardous alcohol consump-
tion and for alcohol-related harm [9]. Reductions in alco-
hol problems of a similar magnitude and in health service
utilisation have also been identified [10].
Motivational Interviewing (MI), a well-defined interven-
tion [11], has been increasingly prominent within this lit-
erature in more recent years. One systematic review
identifies 31 trials of MI, with alcohol being the most
commonly targeted behaviour [12]. MI has been defined
as "a facilitative, patient-centred counselling style for
helping people explore and resolve ambivalence [11]."
Brief adaptations of this counselling style offer promising
potential to optimise the effectiveness of brief interven-
tions. However, very little is known about the salience and
applicability of these interventions in Russia – a country
with a distinctive pattern of heavy drinking.
Aims of the study
The study is a trial to explore the efficacy and acceptability
of a brief intervention aimed at reducing the prevalence of
hazardous drinking in working age men in a typical Rus-
sian city (Izhevsk). This will prepare the ground for subse-
quent effectiveness evaluations in a range of routine
service settings with different populations of hazardous
drinkers. Experience conducting this trial will provide an
indication of the extent of possible benefit specifically
within Russia. In addition, dissemination of information
about the trial and its results is expected to contribute
directly to improving understanding (locally, nationally
and internationally) of the nature of this major problem
in Russia and the required responses.
Methods/Design
The study will be an individually randomised two-armed
parallel group exploratory trial.
Hypotheses
Primary hypothesis
A brief adaptation of MI will be effective in reducing self-
reported hazardous drinking at 3 months.
Secondary hypotheses
MI will be effective in reducing self-reported past week
beverage alcohol consumption, alcohol dependence and
related problems at 3 months and at 12 months. MI will
also be effective at 12 months in reducing self-reported
hazardous drinking, alcohol dependence and related
problems, proxy reported hazardous drinking, and recent
alcohol use as indicated by bio-markers.BMC Health Services Research 2008, 8:69 http://www.biomedcentral.com/1472-6963/8/69
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Trial inclusion criteria
The men recruited into the trial will be drawn from a lon-
gitudinal observational study that is part of the Izhevsk
Family Study II. This is based on 1750 men who were the
controls in a case-control study of premature mortality
conducted 2003–5 [7] supplemented by a further 250
men recruited using an identical protocol over a two
month period in 2006. At initial recruitment to the case-
control study, the men were aged 25–54 years and resi-
dent in Izhevsk. Interviews were conducted with 1750
control proxies, and 1691 of the controls themselves. For
the supplementary group of 250 men, interviews were
again carried out with proxies and with the men them-
selves. Interviewer-administered, structured question-
naires were used to gather information on a wide range of
behaviours and characteristics, including alcohol con-
sumption, tobacco use, a range of socio-economic and
demographic factors, health status, and health-related
behaviours.
Over an 18 month period (2007–8) as part of the longitu-
dinal study we will attempt to recontact all of the 2000
men previously interviewed who are still alive and living
in Izhevsk. Participants, who will be aged between 27 and
59 years of age, will be asked to take part in a re-interview
study involving themselves as well as a proxy informant.
Those who take part in this stage will then be invited to
have a physical examination (referred to as a "Health
Check") a few weeks later, to be carried out by a one of 4
specially trained doctors either in their own home or at a
polyclinic in the city, according to the participant's prefer-
ence.
Eligibility for entry to the trial will be determined accord-
ing to information gathered at the initial re-interviews
with proxy informants who live in the same households as
the participants. These criteria are specified in Table 1.
Men who had a proxy in the last study but now live alone,
or for whom no proxy interview can be obtained, will be
recruited on the basis of self reports of the same measures
and using the same cut-offs.
Trial exclusion criteria
Refusal to have a baseline health check and/or refusal to
be followed up at 3 and 12 months will result in exclusion
from the trial.
Randomisation and consent
Although in most trials, consent to random allocation is
sought before the allocation takes place, there are some
acceptable exceptions when randomisation is carried out
prior to consent (Zelen randomisation), as in this trial
(see Ethics, below).
Table 1: Eligibility and outcome definitions
Eligibility/Outcome Criteria
Eligibility criteria for trial entry based on 
re-contact interview
PROXY reports (or self reports for men living alone) of hazardous drinking defined as one or more 
occurrences of any of the following:
• zapoi in the past year
• surrogates in the past year
• hangover and/or excessive drunkenness and/or going to sleep clothed due to being drunk twice or 
more per week on average over the past year
• weekly average of 250 mls or more of ethanol from beverages over the past year (ie 25+ UK alcohol 
units/week)
Primary outcome (3 months post-
randomisation)
SELF report of hazardous drinking in defined as one or more occurrences of any of the following:
• zapoi in the past month
• surrogates in the past month
• hangover and/or excessive drunkenness and/or going to sleep clothed due to being drunk twice or 
more per week on average over the past year
• 250 mls or more of ethanol from beverages in the past week from beverages (ie 25+ UK alcohol units)
Secondary outcome (12 months post-
randomisation)
SELF report of hazardous drinking defined as one or more occurrences of:
• as above at 3 months
Supplementary secondary outcome (12 
months post-randomisation)
PROXY report of hazardous drinking defined as one or more occurrences of:
• as above at 3 months except proxy rather than self- report
SELF completed:
• AUDIT questionnaire (W.H.O. developed global screening assessment of hazardous drinking [26]
• Leeds Dependency questionnaire [27]
• SIP (Short Index of Problems) questionnaire [28]
Biomarkers of:
• liver damage (GGT, ALT, AST)
• recent heavy drinking (CDT) [29]BMC Health Services Research 2008, 8:69 http://www.biomedcentral.com/1472-6963/8/69
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Data collected at the baseline interview will be sent to the
randomisation service in London, allowing participants
to be allocated to intervention or control prior to their
health check appointment. Minimisation criteria (includ-
ing age, surrogate use in past year, and living alone status)
will be used to ensure a reasonable balance with respect to
the principal known confounding factors.
Signed consent for taking part in the active arm of the trial
will be obtained at the end of the health check. This is the
last of a sequence of consents that the participant will
need to give in the course of recontact as outlined in Table
2. Consent will be obtained differently for the interven-
tion and control groups:
a) Intervention group: Consent will be sought at the time
of the health check by medical personnel involved. They
will be trained to explain the purpose of the trial, provide
written information and answer "frequently asked ques-
tions" about the trial. The consent being requested is (i) to
take part in the intervention and (ii) to provide follow up
data in 3 and 12 months time for the longitudinal study
(even if they are not willing to take part in the interven-
tion);
b) Control group: Consent to take part in the trial will not
be sought from men randomised into the control group as
they need to remain unaware of the trial (see Ethics,
below). However, they will have previously given general




MI will be delivered following completion of the health
check (part of the longitudinal study protocol). An adap-
tation of MI has been developed for the Russian context,
and includes topics such as surrogate drinking and zapoi.
MI involves empathic questioning and listening, with a
view to the development of discrepancy between alcohol
use and other goals and values and the eliciting of person-
alised statements about change. The full intervention
comprises up to four sessions. These will be delivered at
home or in a clinic by specially trained practitioners with
the two core sessions being approximately two weeks
apart, with additional sessions (up to a maximum of 2)
being available upon request. Practitioners have been
trained and supervised in Russian, with a period of prac-
tice-based learning following an introductory workshop.
Approximately 10% of sessions will be audio-recorded for
quality control and supervision purposes.
b) Control group
This group will not receive any intervention other than
having a health check as part of the longitudinal study and
being invited for 3 and 12 month follow ups.
Outcome measures
Follow-up data collection for both groups will take place
after 3 and 12 months
Outcome interviews at 3 and 12 months will be partly
interviewer-administered, and partly self-completed by
participants, in order to replicate the administering of the
same tools at baseline. The primary and secondary out-
comes at 3 and 12 months are summarised in Table 1.
Table 2: Consent
What When Who obtains consent? Comments
Oral consent for interview Baseline recontact interview Interviewer Recorded by interviewer in questionnaire
Oral consent to be recontacted in future 
to assist with research (not-specific)
Baseline recontact interview Interviewer Recorded by interviewer in questionnaire
Expression of interest in health check 
following brief description of health 
check- copy of which to be left with 
participants
Baseline recontact interview Interviewer NOT consent per se, but indication of whether 
interested in taking part and if so, contact details 
(telephone number)
Signed consent for health check 
procedures
Health check Doctor Participants given information on BP and 
anthropometry and questionnaire, and blood 
taking
Signed consent to take part in active 
intervention arm of MI trial
Health check Doctor For subset of participants who are eligible, 
randomized to intervention arm of trial, and 
turn up for health check. Note, no explicit 
consent for being in control arm, beyond oral 
recontact agreementBMC Health Services Research 2008, 8:69 http://www.biomedcentral.com/1472-6963/8/69
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Recruitment rate
Assuming that the overall prevalence of hazardous drink-
ing remains the same over time, we have estimated from
the original Izhevsk Family study data that approximately
25% of the 2000 men initially invited to take part in the
Izhevsk family study II will be eligible for inclusion in the
trial. Assuming a 60% response rate from those invited to
participate in the Izhevsk family study 2 we would expect
to be able to identify 300 hazardous drinkers eligible for
the trial.
Sample size
Based on current MI literature it is expected that 25% of
participants in the intervention arm will stop hazardous
drinking, as those in the control arm will have had mini-
mal contact with the study and will not have been specif-
ically told they are involved in research relating to
alcohol, spontaneous reduction in hazardous drinking of
more than 5% is unlikely. We have selected a difference at
approximately the upper limit of the projected effect size
based on previous meta-analyses [8] as a result of this
unusual characteristic of the study design. We are unaware
that such a Zelen design (see later) has previously been
used in any study of brief alcohol intervention. Power cal-
culations are therefore based on detecting a 20% differ-
ence between randomised groups (from 95% to 75%)
with 90% power at the 5% level of statistical significance.
A sample of at least 130 men (65 in each arm) will there-
fore be required. As randomisation was carried out prior
to consent to MI, we assume that 20% of the participants
in the intervention arm will not agree to receive the inter-
vention. We also assume that there will be a 20% loss to
follow for the 3 month assessment in both trial arms. This
requires inflating the sample size to between 200 and 250
participants.
It should be noted that one aim of this exploratory trial
will be to assess the assumptions behind these calcula-
tions in order to design a definitive study with power to
assess smaller differences which could have nonetheless
have major public health benefits.
Type of analysis
The primary analysis will be based on a difference in the
number of men classified as hazardous drinkers at the 3
month assessment between the randomised groups using
the intention to treat principle. This may dilute the treat-
ment effect but the analysis will not be biased if the loss
to follow up, especially for the primary outcome is similar
between the two randomised groups.
Differential effects by subgroup analyses based on impor-
tant prognostic factors such as age group and severity of
alcohol dependence will be assessed using interaction
tests. We are aware that in this exploratory trial the results
of such analyses will only be indicative.
In addition, the availability of the baseline information
on all participants in the Izhevsk family study II will ena-
ble us to assess the extent to which those people included
in the trial differ systematically from the population sam-
ple from which they were drawn, and will provide external
validation for any trial findings.
Frequency of analysis
An independent Data Monitoring Committee (DMC) will
review, in strict confidence, data for the 3 month out-
comes from the trial approximately 12 months from the
start of the recruitment period. The Chair of the DMC may
also request additional meeting/analyses. In the light of
these data and other evidence from relevant studies, the
DMC will inform the Trial Steering Committee (TSC) if in
their view:
i. There is proof that the data indicate that any part of the
protocol under investigation is either clearly indicated or
clearly contra-indicated either for all patients or a particu-
lar subgroup of patients.
ii. It is evident that no clear outcome will be obtained with
the current trial design.
iii. That they have a major ethical or safety concern.
Publication policy
To safeguard the integrity of the trial, data from this study
will not be presented in public or submitted for publica-
tion without requesting comments and receiving agree-
ment from the Trial Steering Committee. The primary
results of the trial will be presented first to the trial local
investigators, and will be published by the group as a
whole with local investigators acknowledged. The require-
ments for authorship will follow recommended practice
in journal guidelines. A summary of the results of the trial
will be made available on the trial website.
Ethics and confidentiality
In the light of current research, it is not known whether MI
will reduce the extent of hazardous drinking in this con-
text. Hence randomisation as a means of allocating indi-
vidual to be offered or not to be offered MI is the most
ethical approach. Recent work [13] has shown that drink-
ing behaviour can substantially change in response to par-
ticipants' knowledge of being part of an alcohol-related
research project. If we were to follow common ran-
domised controlled trial practice, we would tell all poten-
tial participants about the trial including the alcohol-
specific MI intervention and the alcohol-specific out-
comes, and then ask for consent to be randomised toBMC Health Services Research 2008, 8:69 http://www.biomedcentral.com/1472-6963/8/69
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either arm of the trial. This approach would both create an
'artificial' control group sensitised to alcohol-related
research which did not reflect the current experience of
hazardous drinkers in Izhevsk, and could also seriously
dilute any effect of the MI intervention. In this trial, there-
fore, we are restricting contact with the control group
(especially in relation to being in a trial concentrating on
alcohol) by using a Zelen single consent trial [14,15] in
which the control group is only asked for their consent to
follow up in health-related research, whereas the interven-
tion group is also asked for consent to the MI. This design
is ethically acceptable when the benefit of the interven-
tion is unknown but when detailed knowledge of the trial
and its exact purposes are likely to significantly bias or
influence results [16-25].
Data about patients will be identified by their trial
number to ensure confidentiality.
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